Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979047 | 0.96 | KMT2A (0.33) | KMT2A | |
| SCHEMBL3858517 | 0.86 | KMT2A (0.31) | KMT2A | |
| Methane SCHEMBL3854570 | 0.80 | — | — | |
| SCHEMBL13515132 | 0.71 | KMT2A (0.32) | KMT2A | |
| SCHEMBL16078197 | 0.70 | BCHE (0.32) | KMT2A | |
| SCHEMBL15651890 | 0.68 | — | — | |
| SCHEMBL12628865 | 0.66 | BCHE (0.32) | — | |
| SCHEMBL180595 | 0.63 | — | — | |
| SCHEMBL181042 | 0.63 | ALDH1A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL3138710 | 0.62 | KDM4E (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582123-B2 | Coloring composition comprising at least one azomethine compound with a pyrazolinone unit | L'OREAL S.A. (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20090044348-A1 | Coloring composition comprising at least one azomethine compound with a pyrazolinone unit | L'OREAL S.A. (FR) | 2009-02-19 | — | — | US | disclosed |
| EP-2011787-A1 | Dying composition comprising an azomethin-type compound with a pyrazolinone moiety | L'Oreal (FR) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090044348-A1 | Coloring composition comprising at least one azomethine compound with a pyrazolinone unit | KRT18, KMO, TMPO | KMT2A 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.